2 results
Approved WMORecruiting
Cohort ATo compare the CRR for the combination of pembrolizumab + BCG versus BCG alone in participants with CIS.Cohort B- To compare the EFS between participants who receive pembrolizumab + BCG (reduced maintenance) versus BCG alone- To compare the…
Approved WMOPending
Part 1:To evaluate the effects of 52 weeks of treatment with basmisanil on core symptom domains of Dup15q syndrome (language and social skills) and dailyfunctioning. Part 2:• To evaluate the tolerability and safety of up to 3 years of treatment with…